RKDA Arcadia Biosciences
- 2.0900
- +0.1899+9.99%
- 2.1100
- +0.0200+0.96%
Arcadia Biosciences News
Arcadia Biosciences (RKDA) Announces Date of First Quarter 2024 Financial Results and Business Highlights Conference Call
Arcadia Biosciences, Inc. (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, today announced that it will release its financial and business results for the first
SNDL, Arcadia Biosciences Among Consumer Staples Movers
Arcadia Cold Sets Its Sights on Chicago
Company finalizing plans for multi-facility footprint in the Chicagoland market for their next two cold storage facilities. ATLANTA, April 17, 2024 /PRNewswire/ -- Arcadia Cold, a leading cold stor
Arcadia Raises $50M to Accelerate Product Innovation and Fuel Continued Growth
WASHINGTON, April 11, 2024 /PRNewswire/ -- Arcadia, a global utility data and community solar platform, today announced the close of a growth round. This financing will support the continued growth o
Buy Rating on Arcadia Biosciences Fueled by Strategic Initiatives and Innovative Product Launches
HC Wainwright & Co. Reiterates Buy on Arcadia Biosciences, Maintains $10 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Arcadia Biosciences (NASDAQ:RKDA) with a Buy and maintains $10 price target.
Arcadia Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/05/2024 392.61% HC Wainwright & Co. → $10 Reiterates Buy → Buy 08/28/2023 392.61% HC Wainwright & Co. $
Arcadia Biosciences, Inc. (NASDAQ:RKDA) Q4 2023 Earnings Call Transcript
Buy Rating Affirmed for Arcadia Biosciences Amidst Growth and Strategic Shifts
Arcadia Biosciences Full Year 2023 Earnings: Misses Expectations
Earnings Call Summary | Arcadia Biosciences(RKDA.US) Q4 2023 Earnings Conference
The following is a summary of the Arcadia Biosciences, Inc. (RKDA) Q4 2023 Earnings Call Transcript:Financial Performance:Arcadia reported Q4 revenues of $1.2 million, up 57% compared to Q4 2022, driv
Recap: Arcadia Biosciences Q4 Earnings
Arcadia Biosciences (NASDAQ:RKDA) reported its Q4 earnings results on Thursday, March 28, 2024 at 04:05 PM.Here's what investors need to know about the announcement.EarningsArcadia Biosciences beat es
Arcadia Biosciences GAAP EPS of -$2.10 Beats by $0.48, Revenue of $1.17M Misses by $0.58M
Press Release: Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2023 Financial Results and Business Highlights
Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2023 Financial Results and Business Highlights -- Second continuous year of gross profit growth -- -- Total SG&A expenses declined t
Arcadia Biosciences 4Q Rev $1.17M >RKDA
Arcadia Biosciences 4Q Rev $1.17M >RKDA
Earnings Scheduled For March 28, 2024
Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million. • Shimmick (NASDAQ:SHIM) is estimated
Earnings Outlook For Arcadia Biosciences
Arcadia Biosciences (NASDAQ:RKDA) is set to give its latest quarterly earnings report on Thursday, 2024-03-28. Here's what investors need to know before the announcement.Analysts estimate that Arcadia
Earnings Week Ahead: Walgreens Boots Alliance, Carnival, GameStop and More
Arcadia Biosciences Receives Notice Of Allowance For US Patent Application 17/402,216 Titled "PLANTS WITH REDUCED LIPASE 1 ACTIVITY (FOR IMPROVED SHELF-LIFE, STABILITY, RANCIDITY, AND IMPROVED FLAVOR OF A PLANT PRODUCT)".
Arcadia Biosciences Receives Notice Of Allowance For US Patent Application 17/402,216 Titled "PLANTS WITH REDUCED LIPASE 1 ACTIVITY (FOR IMPROVED SHELF-LIFE, STABILITY, RANCIDITY, AND IMPROVED FLAVOR
Arcadia Biosciences (RKDA) Announces Date of Fourth Quarter 2023 Financial Results and Business Highlights Conference Call
Arcadia Biosciences, Inc. (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, today announced that it will release its financial and business results for the fourth
Analysis
Price Target
No Data
